News

Cognition Therapeutics has announced the dosing of the first Alzheimer’s patient in a Phase 1b clinical trial of its drug candidate, CT1812, for the treatment of mild to moderate Alzheimer’s disease (AD). CT1812 is a proprietary, first-in-class, orally available, drug-like small molecule designed to displace bound amyloid beta oligomers (molecules thought to be…

Brain training can improve both memory and mood in people with mild cognitive impairment, but once a dementia diagnosis has been made, the training no longer has an impact. In the study, “Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review…

Researchers from Iran show in the first human trial that probiotics appear to improve brain cognition in humans. The study, “Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial,” was published in the open-access journal Frontiers in Aging Neuroscience.

A new research study has found that older, cognitively normal adults with elevated levels of cortical amyloid, the protein linked to Alzheimer’s, are much more likely to report feeling lonely and socially isolated regardless of their circumstances. These findings support the potential role of loneliness in preclinical Alzheimer’s disease.

AdAlta and Crossbeta Biosciences have entered into a commercialization agreement, granting Crossbeta with a license to three beta-amyloid oligomer (AßO)-specific shark antibodies, considered to have disease-specific potential for the diagnosis and treatment of Alzheimer’s disease (AD). These three shark antibodies were identified under a December 2013 agreement between…

Merck’s amyloid-lowering drug, verubecestat, has proceeded to Phase 3 clinical trials after early studies showed it safely lowered the levels of amyloid-beta, the protein linked to neurodegeneration in the brains of Alzheimer’s disease patients. Although the news may be reason for optimism, it remains to be seen if the treatment…

Vaccine development strategies for Alzheimer’s disease should attempt to mirror the natural immunity against toxic amyloid-beta, instead of venturing on uncertain paths, Dr. Dante Marciani argued in a feature article discussing Alzheimer’s disease vaccine development. The feature, “Rejecting the Alzheimer’s disease vaccine development for the wrong reasons,” which recently…

Alzheimer’s disease starts with neurodegenerative changes in basal brain structures, and spreads to more superficial layers as the disease progresses, new research reports — a finding that challenges the widely held view that the disease originates in the brain’s cortex. The findings, reported in the study, “Basal forebrain degeneration…

Dr. David Satcher, the former U.S. Surgeon General, was named to the Board of Directors of UsAgainstAlzheimers (UsA2), where he will contribute his voice and influence to the non-profit organization as it advocates for greater urgency and action against Alzheimer’s disease. Satcher, who was a four-star admiral in the United States Public Health…

Abnormalities in the brain’s cellular power plants, known as mitochondria, may drive early Alzheimer’s processes — even before the telltale amyloid plaque that marks the disease starts forming in the brain. The finding suggests that treatments that target the abnormal energy-making processes may be a new way of approaching Alzheimer’s…